The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of microbiota specific circulating memory T cells in response to immunotherapy.
 
Federica Gattazzo
No Relationships to Disclose
 
Roxanne Birebent
No Relationships to Disclose
 
Isabelle Lebhar
No Relationships to Disclose
 
Marie Xiberras
No Relationships to Disclose
 
Mathias Marques
No Relationships to Disclose
 
Anna Reni
No Relationships to Disclose
 
Caroline Flament
No Relationships to Disclose
 
Adele Bonato
No Relationships to Disclose
 
Lorenzo Belluomini
Speakers' Bureau - AstraZeneca/MedImmune; Roche
Research Funding - Bristol Myers Squibb
Travel, Accommodations, Expenses - Astrazeneca; Novartis; Takeda
 
Hugo Chanfreau-Paris
No Relationships to Disclose
 
Agathe Carrier
No Relationships to Disclose
 
Benjamin Besse
Honoraria - Abbvie (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Hedera Dx (Inst); Janssen (Inst); MSD (Inst); Roche (Inst); Sanofi/Aventis (Inst); Springer Healthcare Ltd (Inst)
Consulting or Advisory Role - Abbvie (Inst); BioNTech SE (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); CureVac (Inst); Da voltera (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); F. Hoffmann LaRoche (Inst); Genmab (Inst); Immunocore (Inst); Janssen (Inst); Lilly (Inst); MSD Oncology (Inst); OSE Immunotherapeutics (Inst); Owkin (Inst); PharmaMar (Inst); Regeneron (Inst); Sanofi/Aventis (Inst); Taiho Oncology (Inst); Turning Point Therapeutics (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); BeiGene (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Enliven Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); Nuvalent, Inc. (Inst); OSE Immunotherapeutics (Inst); PharmaMar (Inst); Prelude Therapeutics (Inst); Roche/Genentech (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Laurence Albiges
Consulting or Advisory Role - Astellas Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - BMS; Ipsen; MSD; Pfizer
 
Jordi Ramon
No Relationships to Disclose
 
Claudia Parisi
No Relationships to Disclose
 
Marie Deroussent
No Relationships to Disclose
 
Franck Berthier
No Relationships to Disclose
 
Carolina Alves Costa Silva
No Relationships to Disclose
 
Lisa Derosa
No Relationships to Disclose